Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-02-01 | 2025-01-14 |
| Drug Identification Number | 02499738 | 02499738 |
| Brand name | CEFTRIAXONE INJECTION, USP | CEFTRIAXONE INJECTION, USP |
| Common or Proper name | Ceftriaxone Injection USP 2000 mg / 50 mL | Ceftriaxone Injection USP 2000 mg / 50 mL |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | CEFTRIAXONE | CEFTRIAXONE |
| Strength(s) | 2000MG | 2000MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS | INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | CA2G3505– 24 bags/case | CA2G3505– 24 bags/case |
| ATC code | J01DD | J01DD |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-01-20 | 2025-01-20 |
| Actual start date | 2025-01-20 | 2025-01-20 |
| Estimated end date | 2025-01-31 | 2025-01-31 |
| Actual end date | 2025-01-31 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Potential shortage is due to delays in manufacturing and shipping, and we expect to be back in stock by Jan 31st. | Potential shortage is due to delays in manufacturing and shipping, and we expect to be back in stock by Jan 31st. |
| Health Canada comments |